

Provider Bulletin

News and Information



May 15, 2025

Ketamine infusion policy

On July 1, 2025, UCare's Ketamine intravenous drug policy takes effect for members in all UCare lines of business. Ketamine is considered investigational for the following conditions and will not be covered:

- Psychiatric disorders (including, but not limited to depression, bipolar disorder and posttraumatic stress disorder)
- Chronic pain (including, but not limited to nonmalignant pain, fibromyalgia, neuropathic pain, Complex Regional Pain Syndrome and Reflex Sympathetic Dystrophy)
- Headaches

Prior authorization is not applicable for Ketamine infusions as it is considered excluded for these investigational uses. Additionally, UCare will not review excluded uses for medical necessity.

Policy

Providers will find this policy and others in [UCare's Medical Drug Policies](#) library on July 1, 2025.

Contact UCare's Provider Assistance Center at 612-676-3300 or 1-888-531-1493 toll-free, Monday through Friday, 8 am – 5 pm with questions.